ArticleEuropean journal of nuclear medicine and molecular imaging2022
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 42 citations in OpenAlex.
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Selective Chemistry Enables Simultaneous ImmunoPET and Radioimmunotherapy with a Dual-Labeled Probe.JACS Au · 2026Article
- Preliminary feasibility of pre-treatment F-18-PSMA-1007 PET/CT in dose prediction for Lu-177-PSMA-I&T therapy.Acta oncologica (Stockholm, Sweden) · 2026Article
- Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study.European journal of nuclear medicine and molecular imaging · 2026Article
- Zwitterionic Modification of PSMA Ligands Reduces Off-Target Binding and Tissue Retention.Journal of medicinal chemistry · 2026Article
- Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression.EJNMMI research · 2026Article
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- Article
- The Evaluation of (1Molecules (Basel, Switzerland) · 2025Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- First real-world clinical experience with [European journal of nuclear medicine and molecular imaging · 2025Article
- Isopeptidic Desferrioxamine Analogues: The Role of Hydroxamate Spacing for Chelation of ZrChemMedChem · 2025Article
- Improvement of End-of-Synthesis Radiochemical Purity ofPharmaceutics · 2024Article
- Outstanding increase in tumor-to-background ratio over time allows tumor localization by [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate.Pharmaceuticals (Basel, Switzerland) · 2024Article
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.EJNMMI radiopharmacy and chemistry · 2024Review
- Evaluation of the tolerability and safety of [BMC cancer · 2024Article
- Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study.Theranostics · 2024Article
- From Bench to Bedside: Patient-Oriented Radiopharmaceutical Development in Nuclear Medicine Based on the Example of [Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
rationaleProlonged in vivo evaluation of PSMA tracers could improve tumor imaging and patient selection for MATERIALS AND
methodsPSMA ligands were labeled with 50-55 MBq [
results
conclusionPSMA-617 and PSMA-I&T were successfully labeled with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.